Hemogenyx Pharmaceuticals PLC Collaboration with Johnson & Johnson Innovation (9667D)

TIDMHEMO

RNS Number : 9667D

Hemogenyx Pharmaceuticals PLC

15 October 2018

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Immugenyx Enters Collaboration with Johnson & Johnson Innovation

Hemogenyx Pharmaceuticals Plc (LSE: HEMO; Hemogenyx), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its wholly owned subsidiary, Immugenyx, LLC ("Immugenyx"), has entered into a collaboration agreement with Janssen Research & Development, LLC ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.

Immugenyx will collaborate with Janssen on the development of a model of systemic lupus erythematosus (SLE), the most common form of Lupus, using its advanced hematopoietic chimeras (AHC). AHC, a new type of humanised mouse with a functional human immune system, is being developed by Immugenyx as an in vivo platform for disease modelling and drug development.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "As a company committed to the development of novel therapeutic products for patients suffering from blood and severe autoimmune diseases, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for autoimmune diseases."

According to the terms of the agreement, Immugenyx will collaborate with Janssen on research activities that are determined by a mutually approved research plan. Immugenyx shall own the humanised mouse model of Lupus to be developed in collaboration with Janssen. Immugenyx shall grant to Janssen and its Affiliates a perpetual, irrevocable, non-exclusive, fully-paid-up, transferable, worldwide, license to use the Lupus model solely for their own internal research and product development purposes. Financial terms of the collaboration are not disclosed.

Enquiries:

 
 Hemogenyx Pharmaceuticals Limited                                                    www.hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive Officer                                          Via Walbrook PR 
  & Co-Founder 
 Sir Marc Feldmann, Executive Chairman 
 
 Northland Capital Partners Limited                                            Tel: [phone] 
 Matthew Johnson, Vadim Alexandre, Dugald J 
  Carlean 
 
 Peterhouse Corporate Finance Limited                                          Tel: [phone] 
 Lucy Williams, Duncan Vasey 
 
 Walbrook PR (UK Media & Investor                  Tel: [phone] or [e-mail] 
  Relations) 
 Paul McManus                                                                  Mob: [phone] 
 
 US Media enquiries 
 Lowell Goodman                                     Tel: [phone] or [e-mail] 
 
 

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility ("Hemogenyx").

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risk of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCZMMMGZDDGRZM

(END) Dow Jones Newswires

October 15, 2018 02:00 ET (06:00 GMT)